Seagen abstract hits best case scenario, says RBC Capital

RBC Capital says the European Society for Medical Oncology late-breaking abstracts were inadvertently de-embargoed ahead of the schedule, with the results from Seagen’s (SGEN) EV-302 and Amgen’s (AMGN) as notable. Seagen’s EV-302 hit RBC’s best case scenario, which should support full registration and drive greater commercial uptake of Padcev in first-line metastatic urothelial cancer regardless of cis-eligibility, the analyst tells investors in a research note. For Amgen, the firm says tarlatamab’s profile in DeLLphi-301 was solid with improved efficacy versus standard of care in small cell lung cancer, which could strengthen the case for potential accelerated approval.